Edition:
United States

Momenta Pharmaceuticals Inc (MNTA.OQ)

MNTA.OQ on NASDAQ Stock Exchange Global Select Market

21.90USD
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
$21.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
194,285
52-wk High
$24.85
52-wk Low
$11.85

Chart for

About

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20... (more)

Overall

Beta: 1.70
Market Cap(Mil.): $1,699.20
Shares Outstanding(Mil.): 77.59
Dividend: --
Yield (%): --

Financials

  MNTA.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -1.40 -- --
ROI: -26.41 -5.87 13.17
ROE: -29.51 -7.71 15.15

BRIEF-Momenta Pharmaceuticals Q1 Loss Per Share $0.63

* MOMENTA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 08 2018

BRIEF-Momenta Pharmaceuticals Reports Q4 Earnings Per Share $0.18

* MOMENTA PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Feb 21 2018

BRIEF-Momenta Pharmaceuticals Announces FDA Approval And Launch Of Glatopa

* MOMENTA PHARMACEUTICALS ANNOUNCES FDA APPROVAL AND LAUNCH OF GLATOPA® (GLATIRAMER ACETATE INJECTION) 40 MG/ML

Feb 13 2018

BRIEF-Momenta Pharmaceuticals Announces Positive Outcome For Contracted Glatopa

* MOMENTA PHARMACEUTICALS ANNOUNCES POSITIVE OUTCOME FOR CONTRACTED GLATOPA (GLATIRAMER ACETATE INJECTION) FILL/FINISH MANUFACTURER Source text for Eikon: Further company coverage:

Jan 30 2018

BRIEF-Momenta Pharmaceuticals Planning For Glatopa 40 Mg Launch In 2H 2018 However

* MOMENTA PHARMACEUTICALS - CO PLANNING FOR GLATOPA 40 MG LAUNCH IN 2H 2018; HOWEVER, POTENTIAL REMAINS FOR 1H 2018 LAUNCH - SEC FILING Source text:(http://bit.ly/2CTkx5R) Further company coverage:

Jan 08 2018

BRIEF-Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof Of Mechanism For M281

* MOMENTA PHARMACEUTICALS REPORTS POSITIVE TOP-LINE PHASE 1 DATA SHOWING PROOF OF MECHANISM FOR M281, AN ANTI-FCRN MONOCLONAL ANTIBODY, IN HEALTHY VOLUNTEERS

Jan 05 2018

Momenta, Mylan plan trial of biosimilar to Regeneron eye drug

Momenta Pharmaceuticals Inc and Mylan NV plan to begin a pivotal clinical trial of a biosimilar to Regeneron Pharmaceuticals Inc's blockbuster eye drug Eylea in the first half of this year, the two companies said on Wednesday.

Jan 03 2018

Momenta, Mylan plan trial of biosimilar to Regeneron eye drug

Jan 3 Momenta Pharmaceuticals Inc and Mylan NV plan to begin a pivotal clinical trial of a biosimilar to Regeneron Pharmaceuticals Inc's blockbuster eye drug Eylea in the first half of this year, the two companies said on Wednesday.

Jan 03 2018

BRIEF-Momenta And Mylan Announce Development Strategy For Proposed Biosimilar To Eylea

* MOMENTA AND MYLAN ANNOUNCE DEVELOPMENT STRATEGY FOR M710, A PROPOSED BIOSIMILAR TO EYLEA® (AFLIBERCEPT)

Jan 03 2018

Competitors

Earnings vs. Estimates